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Despite the successes of tyrosine kinase inhibitors (TKIs) in improving outcomes in patients with chronic
myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph þ ALL), allogeneic
hematopoietic stem cell transplantation (HSCT) continues to be an important and potentially curative option
for selected patients with either disease. After HSCT, TKIs are increasingly being used to treat or prevent
disease relapse, and practice patterns suggest that these TKIs are often chosen empirically without regard to
pre-HSCT mutation status. We investigated whether ABL kinase domain mutations persist after trans-
plantation and, thus, whether pre-HSCT mutation status should inform the selection of post-HSCT TKIs in
these patients. We retrospectively analyzed adults who underwent allogeneic HSCT for CML and Ph þ ALL at
our institution between 2000 and 2010, and we identiﬁed subjects who had detectable BCR-ABL transcripts
by polymerase chain reaction (PCR), as well as available RNA for Sanger sequencing of the ABL kinase domain,
in both the pre- and post-HSCT settings. In total, 95 CML and 20 Ph þ ALL patients with positive PCR tran-
scripts were identiﬁed, of which 10 (10.5%) and 4 (20.0%), respectively, were found to have pre-HSCT ABL
kinase mutations known to confer TKI resistance. In 9 (64.2%) of these 14 patients, the same kinase mutation
was also detectable at an average time of 191 days after HSCT. Seven (50.0%) of the 14 harboring mutations
had relapsed/refractory disease by last follow-up, of which, in retrospect, 6 had received a predictably
ineffective TKI within the ﬁrst 100 days after transplantation based on our mutation analysis. These data
support the idea that pre-existing mutations in the ABL kinase domain, frequently associated with resistance
to TKIs and prevalent in a transplantation population, are persistently detectable in the majority of patients
after transplantation. We propose that such resistance patterns should be considered when selecting TKIs in
the post-HSCT setting, including clinical trials of post-HSCT TKI prophylaxis.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION In the current treatment approach for CML, allogeneic
Tyrosine kinase inhibitors (TKIs) remain the front-line
therapy for patients with chronic myeloid leukemia (CML)
and also improve outcomes when incorporated into induc-
tion and maintenance regimens for those with Philadelphia-
positive acute lymphoblastic leukemia (Phþ ALL). Resistance
to TKIs is commonly due to the emergence of clones con-
taining point mutations in the ABL kinase domain of BCR-
ABL, occurring in as many as 30% to 60% of CML patients
with imatinib resistance [1,2], as well as in over one third of
Ph þ ALL patients at the time of diagnosis [3]. More than 100
ABL kinase domain mutations associated with TKI resistance
have been described [4].hematopoietic stem cell transplantation (HSCT) is generally
reserved for patients who fail or are intolerant of TKI therapy
or for those with advanced phase disease. Transplantation is
also a potentially curative option for Ph þ ALL patients with
HLA identically matched related or unrelated donors. Relapse
after HSCT is fairly common in both advanced phase CML
(30% to 40%) [5,6] and Ph þ ALL (30% to 60%) [7]. Therapeutic
strategies to treat post-HSCT relapse historically consisted of
withdrawal of immunosuppression or donor lymphocyte
infusions, though several studies have shown efﬁcacy in
treating relapsed CML or Ph þ ALL with TKIs [8-15]. An
increasing number of studies have also evaluated the pro-
phylactic use of TKIs after transplantation in high-risk pa-
tients, including those with detectable BCR-ABL at the time
of transplantation, though there are very limited data to
guide their selection and administration [16-19].
In addition to cost considerations, the selection of post-
transplantation TKIs is based, at least in part, on toxicity
proﬁles of the available agents. The bulk of retrospective
and prospective studies using imatinib indicate that it is
generally well-tolerated after HSCT, even in the early
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the efﬁcacy and safety of second-generation TKIs after HSCT
are limited to small case series or individual case reports
[13,14,22-26]. In this limited experience, however, there is at
least some indication that toxicity after HSCT may be more
pronounced with the newer drugs. In 1 of the larger series
reporting on the use of dasatinib in patients with relapsed
CML or Ph þ ALL, all 7 patients taking dasatinib at the 70 mg
twice daily dose, beginning at amean of 9months after HSCT,
required interruption or dose reduction for gastrointestinal,
hematologic, pulmonary, or hepatic toxicity [13]. Additional
anecdotal evidence from an ongoing clinical trial at our
institution increasingly suggests that nilotinib may be asso-
ciated with considerably more hematologic toxicity than
imatinib in the early post-transplantation period (data un-
published). The second-generation TKIs have also been
associated with greater vascular toxicity compared with
imatinib, which may be of concern in the post-
transplantation setting, given that cardiovascular risk
factors, including diabetes, hypertension, and hyper-
triglyceridemia, are already more prevalent in allogeneic
transplantation recipients [27].
Considering that subpopulations of leukemic cells may
exist within a patient, with some harboring a resistance
mutation and others not, it is reasonable to suspect that the
relative proportions of these subpopulations would be
affected by the selective pressures of continued TKI exposure
versus cessation of TKI exposure, as well as of the trans-
plantation conditioning regimen. The question arises
whether pre-HSCT mutation status should guide the selec-
tion of post-HSCT TKI prophylaxis. Therefore, we sought to
investigate if speciﬁc ABL kinase domain mutations persist in
CML and Ph þ ALL patients after HSCT.
METHODS
Study Population
In this retrospective analysis, all patients who had undergone allogeneic
HSCT at our center between January 1, 2000 and July 15, 2010 for CML or
Ph þ ALL, and who were at least 18 years of age at the time of trans-
plantation, were screened for inclusion in the study. Because of logistical
changes in the acquisition and processing of patient samples in 2010, we
were not able to obtain RNA for laboratory testing after this time, and,
therefore, this analysis was restricted to those patients undergoing trans-
plantation within the speciﬁed time period. We limited chart review and
laboratory analysis to those subjects with a history of any positive p210 or
p190 BCR-ABL transcript by polymerase chain reaction (PCR) in both the pre-
and post-HSCT settings. Patients without available records for chart review
and those without available paired pre- and post-HSCT RNAwere excluded.
All clinical investigations were conducted according to Declaration of Hel-
sinki principles.
Molecular Analysis
Total RNAwas extracted from pre-HSCT and post-HSCT bone marrow or
peripheral blood samples using TRIzol reagent (Life Technologies, Grand
Island, NY). An initial RT-PCR step with a nested PCR was used to amplify a
928-bp product spanning exons 4 to 9 (codons 199 to 507) of the ABL kinase
domain in p210 and/or p190 transcripts. Bidirectional Sanger sequencing of
the PCR product was performed using an Applied Biosystems 3730xl
Analyzer (Life Technologies, Grand Island, NY). Pre-HSCT samples were ﬁrst
screened formutations, and inpatientswith amutation identiﬁed, the paired
post-HSCT samples were ampliﬁed and then sequenced in a similar fashion.
RESULTS
Pretransplantation Patient Characteristics
A total 252 adult patients underwent HSCT for CML dur-
ing the speciﬁed study period. Of these, archived RNA sam-
ples were not available for 116 patients, and another 40
didn’t have positive BCR-ABL transcripts both before and
after HSCT. One patient lacked sufﬁcient available records forchart review. Therefore, we identiﬁed 95 CML patients for
inclusion in the study. Similarly, out of a total 91 adult pa-
tients undergoing HSCT for Phþ ALL during the study period,
45 lacked available RNA samples for testing, and 26 didn’t
have positive BCR-ABL transcripts both before and after
HSCT, leaving 20 subjects for inclusion in the study.
Clinical characteristics for both groups of patients are
detailed in Table 1. History was notable for pre-HSCT TKI
therapy in 61 (64.2%) CML patients with a mean duration of
pre-HSCT exposure of 12.3 months. Thirty-three (34.7%) CML
patients had demonstrated TKI resistance or failure before
transplantation, with the majority proceeding to trans-
plantation for reasons other than TKI failure. In fact, 34
(35.8%) underwent transplantation without prior TKI ther-
apy, all in the early study period between January 2000 and
July 2002; all patients who underwent transplantation since
the latter half of 2002 were treated with at least 1 TKI before
transplantation. Thirty-three (34.7%) underwent trans-
plantation because of a history of accelerated phase or blast
crisis, of which 11 were in second or higher chronic phase at
the time of HSCT. Eighteen (18.9%) underwent trans-
plantation for other reasons, which included issues related to
drug cost or availability, as well as patient/physician prefer-
ence. Indications for HSCT were not mutually exclusive (for
example, blast crisis and TKI failure).
Among Phþ ALL patients, 18 (90.0%) received a TKI before
transplantation, for a mean duration of 10.6 months. Nine-
teen (95.0%) Ph þ ALL patients underwent transplantation in
complete remission. Two Ph þ ALL patients had previously
undergone a ﬁrst allogeneic transplantation and had subse-
quently relapsed. The majority of patients (88.4% of CML and
65.0% of Ph þ ALL patients) received myeloablative
conditioning.Post-Transplantation Therapy
By the time of last clinical follow-up at our institution,
corresponding with a mean duration of 2.1 years post-
transplantation follow-up (range, .2 to 11.1 years), a total of
29 (30.5%) CML and 14 (70.0%) Ph þ ALL patients received a
TKI at some point in the post-HSCT setting. All 14 Ph þ ALL
patients receiving a TKI after transplantation initially
received the drug for prophylaxis, beginning at a mean of 1
month after HSCT (range, .5 to 2 months). Of these, 4 ulti-
mately relapsedd2 of whom had pretransplantation BCR-
ABL mutations and 2 of whom did not.
Among the 29 CML patients receiving post-HSCT TKIs, 10
(34.5%) were initially started on TKI therapy for treatment of
refractory/relapsed disease, beginning at a mean of 1.5
months after HSCT for the 6 with refractory disease and
beginning at a mean of 5.3 months after HSCT for the 4 with
disease relapse after transplantation. In addition, 19 (65.5%)
received post-HSCT TKI prophylactically, beginning at a
mean of 11.0 months after HSCT, overall. Most began the
TKI between .8 and 16 months after HSCT, although 2
outlier patients (both who underwent transplantation in
2001) started TKIs at 51 and 101 months after HSCT,
respectively, because of molecular positivity. Of the 19 CML
patients receiving TKI prophylaxis, 6 patients ultimately
developed cytogenetic or hematologic relapsed2 had pre-
transplantation BCR-ABL mutations and 4 did not. The time
to initiation of post-HSCT TKI was lower among the 6 CML
patients who relapsed on prophylaxis (mean, 1.3 months
after HSCT) compared with the 10 without relapse (mean,
15.4 months after HSCT), suggesting that clinical
Table 1
Clinical Characteristics of CML and Ph þ ALL Patients
Characteristics CML (n ¼ 95) Ph þ ALL (n ¼ 20)
Age at HSCT, median (range), yr 41.1 (18-66) 42.9 (22-63)
Gender
Male 55.0% 55.0%
Female 45.0% 45.0%
Disease status before HSCT
CP1 60 (63.1%)
CP2þ 13 (13.7%)
AP/BC 22 (23.2%)
CR1 14 (70.0%)
CR2þ 5 (25.0%)
Relapse 1 (5.0%)
Indication for HSCT*
No TKI therapy 34 (35.8%)
TKI failure 33 (34.7%)
AP/BC 33 (34.7%)
Othery 18 (18.9%)
Conditioning
Myeloablative 84 (88.4%) 13 (65.0%)
Nonmyeloablative 11 (11.6%) 7 (35.0%)
Pre-HSCT
Received TKI?
No 34 (35.8%) 2 (10.0%)
Yes 61 (64.2%) 18 (90.0%)
1 TKI 52 (54.7%) 13 (65.0%)
2 TKIs 7 (7.4%) 5 (25.0%)
3 TKIs 2 (2.1%) d
Type and durationz of TKI
Imatinib 52 (54.7%) 11.3 mo 16 (80.0)% 9.5 mo
Dasatinib 7 (7.4%) 7.2 mo 4 (20.0%) 4.5 mo
Nilotinib 2 (2.1%) 5.0 mo d
Post-HSCT
Received TKI?
No 66 (69.5%) 6 (30.0%)
Yes 29 (30.5%) 14 (70.0%)
Type and durationz of TKI
Imatinib 25 (26.3%) 10.3 þ mo 12 (60.0%) 8.6 þ mo
Dasatinib 5 (5.3%) 24.0 þ mo 4 (20.0%) 6.5 þ mo
Nilotinib 3 (3.2%) 6.0 þ mo 2 (10.0%) 9.5 mo
Ponatinib 1 (1.1%) 3.0 mo d
Initial indication for post-HSCT TKI
Relapsed/refractory disease 10 (34.5%) 0 (0.0%)
Prophylaxis/molecular MRD 19 (65.5%) 14 (100.0%)
CP indicates chronic phase; AP, accelerated phase; BC, blast crisis; CR, complete remission; MRD, minimal residual disease.
Data presented are n (%) unless otherwise indicated.
* Indications for HSCT are not mutually exclusive (eg, blast crisis and TKI failure).
y “Other” indications for HSCT include patient/physician preference.
z Mean duration of TKI use before and after HSCT (for those who received the drug). At the time of last follow-up, post-HSCT TKI use was ongoing in some
patients.
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prophylaxis sooner.Pretransplantation Mutation Analysis
Sequencing revealed 12 different ABL kinase mutations in
10 (10.5%) CML and in 4 (20.0%) Ph þ ALL pre-HSCT samples.
All 14 patients harbored at least 1 mutation previously re-
ported to be associated with resistance to 1 or more TKIs
[4,28-31]. Mutations occurred across the kinase domain,
including the TKI-binding site, P-loop and A-loop: L248V,
G250E, Q252H, Y253H, T315I, F317L, M351T, F359V, R362G,
E450K, E459K, and F486S. Three patients were found to carry
the T315I mutation. One patient (patient 8, Figure 1) had 2
mutations: L248V and R362G. Three additional patients were
found to have a deletion in exon 7, a common splice variant
not associated with imatinib resistance [32].Persistence of Mutations after Transplantation
In 9 (64.2%) of the 14 patients with pre-HSCT mutations,
the same mutation conferring TKI resistance was alsodetectable after HSCT an average 191 days after trans-
plantation (range, 25 to 559; Figure 1). Patient 8, who
initially harbored 2 pre-HSCT ABL mutations (L248V and
R362G), had only the L248V mutation detectable after
transplantation. Patient 12 initially harbored only a F359V
mutation before HSCT but was found to have 2 mutations
(F359V and D391G) detectable after HSCT. ABL mutations
were persistently detectable in 7 of 11 (63.6%) patients
receiving myeloablative conditioning and in 2 of 3 (66.6%)
patients receiving nonmyeloablative conditioning.Post-HSCT TKI Therapy and Outcomes in Patients with
ABL Mutations
Among the 14 patients with pre-HSCT mutations, 8
(57.1%) received a TKI in the post-HSCT setting, and 7
(50.0%) demonstrated refractory disease and/or hemato-
logic/cytogenetic relapse after transplantation. Notably, of
the 7 with relapsed/refractory disease, 5 had been given a
predictably ineffective TKI within the ﬁrst 100 days after
HSCT, based on our retrospective mutation analysis
Figure 1. BCR-ABL PCR status and BCR-ABL mutation analysis before and after transplantation in 14 patients with identiﬁed ABL domain kinase mutations. Pre-
transplantation and post-transplantation BCR-ABL transcript levels, as determined by PCR testing, are reported as the ratio of BCR-ABL to BCR, or as qualitatively
negative (“Neg”). Transcript levels are alternatively reported as qualitatively positive (“Pos”) when quantitative results are not available. Samples are also identiﬁed as
being positive for a BCR-ABL kinase domain mutation (purple square), negative for a BCR-ABL kinase domain mutation (orange square), or when mutation testing was
not performed (orange circle). Post-transplantation TKI exposure is indicated for each patient using a bar corresponding to imatinib (I), dasatinib (D), nilotinib (N), or
ponatinib (P), and are shaded pink when the pre-existing mutation is known to confer resistance to the TKI administered or green when the pre-existing mutation is
not expected to confer resistance to the TKI. *Cytogenetic or hematological relapse after HSCT. yPatient 8 was determined to initially harbor 2 ABL mutations (L248V
and R362G) before transplantation but only the L248V mutation was detectable after transplantation. zPatient 12 was found to initially harbor a F359V mutation
before transplantation but 2 mutations (F359V and D391G) were detectable after transplantation.
D.N. Egan et al. / Biol Blood Marrow Transplant 21 (2015) 172e195 187(patients 1, 3, 4, 6, and 9). Three patients with refractory
disease died of disease-related complications (patients 1, 3,
and 4). Patients 6 and 9 both relapsed while receiving
imatinib; however, in patient 9, the mutant clone was no
longer detectable after cessation of imatinib and adminis-
tration of reinduction chemotherapy, though the patient
ultimately died in blast crisis with a BCR-ABLenegative
clone. Patient 7 also initially received a predictably inef-
fective TKI (dasatinib) based on mutation analysis, but was
switched to nilotinib and subsequently achieved a molecu-
lar remission. Two patients received a prophylactic TKI for
which the pre-HSCT mutation is not expected to confer
resistance; however, it is notable that they both relapsed
anyway (patients 10 and 11). Of the 6 patients who did not
receive any TKI therapy after transplantation, 3 tested
negatively for the pre-existing mutation (patients 2, 13, and
14), whereas the other 3 tested positively for the pre-
existing mutation but ultimately became PCR negative as
of last follow-up (patients 5, 8, and 12).It should be noted that in all but 1 case (patient 10), pa-
tients who were PCR positive but without the pre-
transplantation mutation had very low BCR-ABL values
(<.01%); thus, these cases may be “wild-type” simply
because of the relative lack of sensitive detectionwith Sanger
sequencing. The noted exception is patient 10, who before
transplantation had the F386S mutation and relapsed with
wild-type ABL with very high BCR-ABL transcript levels
(105%).
DISCUSSION
Themajority of transplantations for CML are nowdone for
patients who are resistant to multiple TKI agents, and these
cases often will have ABL point mutations [1-3,33]. After
transplantation, persistent leukemic clones may compete
without the selective pressure of a TKI. Given the goal of
preventing post-allograft relapse, and given the different
toxicity spectrum of imatinib and the second generation
TKIs, how should the clinician use the ABL mutation status to
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strated that the clones that persist after allografting are
largely due to the persistence of the ABL-mutated clone
present before transplantation, and thus, prophylactic TKI
use aimed at targeting that ABL clone is a rational strategy.
Data regarding the prevalence or persistence of ABL mu-
tations after HSCT is extremely limited. In 2 retrospective
reviews of dasatinib for treatment of post-transplantation
relapse of CML or Ph þ ALL, authors report that 3 of 6 pa-
tients (50%) and 4 of 7 patients (55%), respectively, were
identiﬁed as carrying resistance mutations; however, no
information on pretransplantation mutation status or
mutation-speciﬁc outcomes is available [13,14]. In 2010,
Jabbour et al. reported on ABL kinase domain sequencing
analysis in 7 CML patients with post-HSCT relapse. Among 4
patients harboring a pre-HSCT mutation, 2 relapsed with the
same mutation, 1 relapsed with a new mutation, and 1
relapsed without a detectable mutation. Patient-speciﬁc TKI
exposure was not reported [34]. Analysis of our cohort of
patients reveals similar ﬁndings: among the 7 patients with
relapsed/refractory disease after transplantation, 5 (71.4%)
relapsed with the same mutation and 2 relapsed without a
detectable mutation. The overall rate of ABL mutation
persistence after transplantation, 64.2% in our cohort, has not
previously been reported.
The emergence of TKI resistance is an example of
Darwinian selection, where wild type and resistant clones
compete under a potentially changing selective pressure.
Jones et al. demonstrated an association between TKI expo-
sure and detection of mutations at the time of disease
recurrence in patients with Ph þ ALL [35]. In addition,
Hanfstein et al. showed that the relative expression of BCR-
ABL mutant alleles within CML patients ﬂuctuated in
response to changes in TKI therapy [36]. These ﬁndings
demonstrate that TKI exposure directly exerts a selective
pressure on speciﬁc clonal populations and they support our
own observation that, in patients with detectable resistance
mutations after transplantation, the administration of TKIs
might confer a selective advantage for any existing drug-
resistant clones. Indeed, in our study, all 3 patients who
received TKI prophylaxis in the setting of a resistance mu-
tation ultimately relapsed.
Our study has practical implications for the design of
studies of post-transplantation TKI prophylaxis. The current
methodology, as illustrated by 4 published prospective trials
in this area, is that patients generally receive an empirically
selected TKI (imatinib in the case of the 4 prospective trials)
regardless of mutation status or prior TKI exposure [16-19].
One could alternatively suggest the empiric use of a second-
or third-generation TKI. However, because the resistance
proﬁles of the newer TKIs, although overlapping, are unique
for each drug, the empiric selection of any single TKI will
almost certainly result in predictable treatment failures in a
subset of those with pre-existing mutations. Indeed, 5 of the
7 patients who relapsed in this cohort had been given a TKI in
the presence of a corresponding mutation conferring resis-
tance against that agent. The administration of effective
antileukemic therapies may be of even greater importance in
the early post-transplantation period when the graft-versus-
leukemia effect has yet to exert its inﬂuence. Therefore, in
addition to considerations of cost and toxicity, we propose
that pretransplantation mutation analysis should also be
regarded when selecting a TKI for post-transplantation
prophylaxis, based on our observations that the majority of
resistance mutations are still detectable aftertransplantation, and that patients often relapse with these
mutant clones despite receiving TKI therapy.
Although this is the largest paired analysis of ABL kinase
domain mutations in a transplantation population, our study
was constrained by the degree with which patients, many of
whom had been referred to our institution for trans-
plantation, remained in our system for clinical follow-up, and
by the incomplete availability of RNA specimens for the
entire transplantation cohort (especially after patients left
our center and returned home). Our overall rate of ABL mu-
tations in CML is lower than others have reported [1,2],
though this is likely due to the large proportion of study
subjects who underwent transplantation without demon-
strated TKI failure. We decided to begin the study period in
2000 to maximize the number of subjects with exposure to
TKIs. However, this resulted in the inclusion of 34 subjects
(35.8% of the study population) who proceeded to trans-
plantation without TKI therapy, all between 2000 and 2002,
when long-term outcomes of imatinib were unknown.
Because the sensitivity of Sanger sequencing for detection of
mutant alleles is estimated to be 20% [37], it is also possible
that low-level mutant clones were present but undetected
either before or after transplantation. Studies employing
more sensitive screeningmethods for ABLmutations reveal a
complex clonal architecture, consisting of a dynamic mix of
compound and polyclonal mutations [38,39]. However, it is
not yet clear how such ultrasensitive mutation analysis and
population complexity should be interpreted, in regards to
clinical decision-making.
In conclusion, we demonstrate that pre-existing muta-
tions in the ABL kinase domain, frequently associated with
resistance to TKIs and prevalent in a transplantation popu-
lation, are persistently detectable in the majority of patients
after transplantation and that such resistance patterns need
to be considered when selecting TKIs in the post-
transplantation setting and when designing clinical trials of
post-transplantation TKI prophylaxis. Further study,
involving larger numbers of patients with resistance muta-
tions and perhaps utilizing more sensitive screening
methods, is required to more clearly understand patterns of
clonal evolution and TKI resistance mutations after he-
matopoietic stem cell transplantation for CML and Ph þ ALL.
ACKNOWLEDGMENTS
This workwas supported in part by the National Institutes
of Health training grant 5-T32-CA009515-28/29.
Financial disclosure statement: D.N.E. and L.B. declare no
competing ﬁnancial interests. J.P.R. has had consulting
agreements with Novartis, BMS, and Ariad, and receives
research contracts from Novartis.
Conﬂict of interest statement: There are no conﬂicts of in-
terest to report.
Authorship statement: D.N.E. and L.B. performed
sequencing experiments. D.N.E. performed chart review,
analyzed data, and wrote the manuscript. J.C.R. designed
experiments and edited the manuscript.REFERENCES
1. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical signiﬁ-
cance of BCR-ABL mutations in patients with chronic myeloid leukemia
treated with imatinib mesylate. Leukemia. 2006;20:1767-1773.
2. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300
patients with BCR-ABL-positive leukemias treated with imatinib in a
single center: A 4.5-year follow-up. Cancer. 2005;103:1659-1669.
3. Soverini S, Vitale A, Poerio A, et al. Philadelphia-positive acute
lymphoblastic leukemia patients already harbor BCR-ABL kinase
D.N. Egan et al. / Biol Blood Marrow Transplant 21 (2015) 172e195 189domain mutations at low levels at the time of diagnosis. Haematologica.
2011;96:552-557.
4. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal
mechanisms of resistance to imatinib (STI571) therapy. Leukemia.
2002;16:2190-2196.
5. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem
cell transplantation for chronic myeloid leukemia in Europe 2006:
transplant activity, long-term data and current results. An analysis by
the Chronic Leukemia Working Party of the European Group for Blood
and Marrow Transplantation (EBMT). Haematologica. 2006;91:513-521.
6. Barrett AJ, Horowitz MM, Ash RC, et al. Bone marrow transplantation
for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Blood. 1992;79:3067-3070.
7. Copelan EA, Crilley PA, Szer J, et al. Late mortality and relapse following
BuCy2 and HLA-identical sibling marrow transplantation for chronic
myelogenous leukemia. Biol Blood Marrow Transplant. 2009;15:
851-855.
8. Kantarjian HM, O’Brien S, Cortes JE, et al. Imatinib mesylate therapy for
relapse after allogeneic stem cell transplantation for chronic myelog-
enous leukemia. Blood. 2002;100:1590-1595.
9. Olavarria E, Ottmann OG, Deininger M, et al. Response to imatinib in
patients who relapse after allogeneic stem cell transplantation for
chronic myeloid leukemia. Leukemia. 2003;17:1707-1712.
10. DeAngelo DJ, Hochberg EP, Alyea EP, et al. Extended follow-up of pa-
tients treated with imatinib mesylate (Gleevec) for chronic myeloge-
nous leukemia relapse after allogeneic transplantation: durable
cytogenetic remission and conversion to complete donor chimerism
without graft-versus-host disease. Clin Cancer Res. 2004;10:5065-5071.
11. Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular re-
missions after treatment with imatinib-mesylate in patients with
failure after allogeneic stem cell transplantation for chronic myeloge-
nous leukemia: results of a prospective phase II open-label multicenter
study. J Clin Oncol. 2005;23:7583-7593.
12. Palandri F, Amabile M, Rosti G, et al. Imatinib therapy for chronic
myeloid leukemia patients who relapse after allogeneic stem cell
transplantation: a molecular analysis. Bone Marrow Transplant. 2007;
39:189-191.
13. Atallah E, Kantarjian H, De Lima M, et al. The role of dasatinib in pa-
tients with Philadelphia (Ph) positive acute lymphoblastic leukemia
(ALL) and chronic myeloid leukemia (CML) relapsing after stem cell
transplantation (SCT). Blood (ASH Annual Meeting Abstracts). 2006;108.
Abstract 4520.
14. Klyuchnikov E, Schafhausen P, Kroger N, et al. Second-generation
tyrosine kinase inhibitors in the post-transplant period in patients with
chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic
leukemia. Acta Haematol. 2009;122:6-10.
15. Wright MP, Shepherd JD, Barnett MF, et al. Response to tyrosine kinase
inhibitor therapy in patients with chronic myelogenous leukemia re-
lapsing in chronic and advanced phase following allogeneic hemato-
poietic stem cell transplantation. Biol Blood Marrow Transplant. 2010;
16:639-646.
16. Olavarria E, Siddique S, Grifﬁths MJ, et al. Posttransplantation imatinib
as a strategy to postpone the requirement for immunotherapy in pa-
tients undergoing reduced-intensity allografts for chronic myeloid
leukemia. Blood. 2007;110:4614-4617.
17. Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administra-
tion of imatinib after hematopoietic cell transplantation for high-risk
Philadelphia chromosome-positive leukemia. Blood. 2007;109:
2791-2793.
18. Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to
posttransplantation imatinib determines outcome in MRD þ
Philadelphia-positive acute lymphoblastic leukemia (Ph þ ALL). Blood.
2005;106:458-463.
19. Pfeifer H, Wassmann B, Bethge W. Randomized comparison of pro-
phylactic and minimal residual disease-triggered imatinib after allo-
geneic stem cell transplantation for BCReABL1-positive acute
lymphoblastic leukemia. Leukemia. 2013;27:1254-1262.
20. Ram R, Storb R, Sandmaier BM, et al. Non-myeloablative conditioning
with allogeneic hematopoietic cell transplantation for the treatment of
high-risk acute lymphoblastic leukemia. Haematologica. 2011;96:
1113-1120.
21. Anderlini P, Sheth S, Hicks K, et al. Re: Imatinib mesylate administra-
tion in the ﬁrst 100 days after stem cell transplantation. Biol Blood
Marrow Transplant. 2004;10:883-884.22. Kang BW, Moon JH, Chae YS, et al. Pre-emptive treatment with nilo-
tinib after second allogeneic transplantation in a Philadelphia
chromosome-positive acute lymphoblastic leukemia patient with high
risk of relapse. Acta Haematol. 2010;123:242-247.
23. Merante S, Colombo AA, Calatroni S, et al. Nilotinib restores long-term
full-donor chimerism in Ph-positive acute lymphoblastic leukemia
relapsed after allogeneic transplantation. Bone Marrow Transplant.
2009;44:263-264.
24. Tiribelli M, Sperotto A, Candoni A, et al. Nilotinib and donor
lymphocyte infusion in the treatment of Philadelphia-positive acute
lymphoblastic leukemia (Phþ ALL) relapsing after allogeneic stem
cell transplantation and resistant to imatinib. Leuk Res. 2009;33:
174-177.
25. Czyz A, Lewandowski K, Kroll R, Komarnicki M. Dasatinib-induced
complete molecular response after allogeneic hematopoietic stem
cell transplantation in Philadelphia chromosome-positive acute
lymphoblastic leukemia resistant to prior imatinib-containing
regimen: a case report and discussion. Med Oncol. 2010;27:
1123-1126.
26. Caocci G, Vacca A, Ledda A, et al. Prophylactic and preemptive therapy
with dasatinib after hematopoietic stem cell transplantation for Phil-
adelphia chromosome-positive acute lymphoblastic leukemia. Biol
Blood Marrow Transplant. 2012;18:652-654.
27. Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease
after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;
110:3463-3471.
28. Kang HY, Hwang JY, Kim SH, et al. Comparison of allele speciﬁc
oligonucleotide-polymerase chain reaction and direct sequencing for
high throughput screening of ABL kinase domain mutations in chronic
myeloid leukemia resistant to imatinib. Haematologica. 2006;91:
659-662.
29. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mu-
tations on response to nilotinib in patients with chronic myeloid leu-
kemia in chronic phase. J Clin Oncol. 2009;27:4204-4210.
30. Redaelli S, Piazza R, Rostagno R, et al. Activity of bosutinib, dasatinib,
and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin
Oncol. 2009;27:469-471.
31. Soverini S, De Benedittis C, Papayannidis C. Drug resistance and BCR-
ABL kinase domain mutations in Philadelphia chromosomeepositive
acute lymphoblastic leukemia from the imatinib to the second-
generation tyrosine kinase inhibitor era: the main changes are in the
type of mutations, but not in the frequency of mutation involvement.
Cancer. 2014;120:1002-1009.
32. Gruber FX, Hjorth-Hansen H, Mikkola1 I, et al. A novel BCR-ABL
splice isoform is associated with the L248V mutation in CML pa-
tients with acquired resistance to imatinib. Leukemia. 2006;20:
2057-2060.
33. Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of
BCR-ABL frequently precede imatinib-based therapy and give rise to
relapse in patients with de novo Philadelphia-positive acute lympho-
blastic leukemia (Ph þ ALL). Blood. 2007;110:727-734.
34. Jabbour E, Cortes J, Santos FP, et al. Results of allogeneic hematopoietic
stem cell transplantation for chronic myelogenous leukemia patients
who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase
domain mutations. Blood. 2007;117:3641-3647.
35. Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in
Philadelphia chromosome-positive acute lymphoblastic leukemia
emerge after therapy with BCR-ABL kinase inhibitors. Cancer. 2008;
113:985-994.
36. Hanfstein B, Muller MC, Kriel S, et al. Dynamics of mutation BCR-ABL-
positive clones after cessation of tyrosine kinase inhibitor therapy.
Haematologica. 2011;96:360-366.
37. Branford S, Rudski Z, Walsh S, et al. Detection of BCR-ABL mutations in
patients with CML treated with imatinib is virtually always accompa-
nied by clinical resistance, and mutations in the ATP phosphate-
binding loop (P-loop) are associated with a poor prognosis. Blood.
2012;102:276-283.
38. Khorashad JS, Kelley TW, Szankasi P, et al. BCR-ABL1 compound mu-
tation in tyrosine kinase inhibitor-resistant CML: frequency and clonal
relationships. Blood. 2013;121:489-498.
39. Soverini S, De Benedittis C, Polakova KM, et al. Unraveling the
complexity of tyrosine kinase inhibitor-resistant populations by ultra-
deep sequencing of the BCR-ABL kinase domain. Blood. 2013;122:
1634-1648.
